The Lancet Haematology in conversation with Podcast By The Lancet Group cover art

The Lancet Haematology in conversation with

The Lancet Haematology in conversation with

By: The Lancet Group
Listen for free

About this listen

Lan-Lan Smith, Editor-in-Chief, Cheryl Lai, Acting Deputy Editor, and Emma Cookson, Senior Editor at The Lancet Haematology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.

A monthly audio companion to the journal, this podcast covers a broad range of topics, from racial and ethnic disparities in leukaemia survival outcomes to resuscitation with blood products compared with saline, the link between mental health and lymphoma to haemolytic disease in newborns, and more.

© 2025 The Lancet Group Biological Sciences Hygiene & Healthy Living Physical Illness & Disease Science
Episodes
  • A panel of the authors on our Adverse Events Series on adverse event reporting in haematological malignancies

    A panel of the authors on our Adverse Events Series on adverse event reporting in haematological malignancies
    Jun 13 2025

    With a growing number of treatment options for blood cancers, understanding the side effects from these treatments and how they affect patients is becoming ever more important. Join a panel of authors from The Lancet Haematology's latest series on Adverse Event reporting to discuss how we can improve clinical trial design and analysis, and translate this data to meaningful, patient-centric care.

    Read the full series here:
    https://www.thelancet.com/series-do/adverse-events-in-haematology-oncology?dgcid=buzzsprout_icw_podcast_13-06-25_lanhaeadverseevents25_lanhae

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Show more Show less
    40 mins
  • Michael Northend on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma

    Michael Northend on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma
    Apr 28 2025

    Dr Michael Northend (University College London Hospitals NHS Foundation Trust, and Cancer Research UK & UCL Cancer Trials Centre, London, UK) joins us to discuss the long-term results of a randomised, phase 3 trial on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma.

    Read the full article:

    https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00034-1/fulltext?dgcid=buzzsprout_icw_podcast_28-04-25_lanhae

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Show more Show less
    16 mins
  • Joanne Verweij and Romy Pothof on fetal and neonatal alloimmune thrombocytopenia

    Joanne Verweij and Romy Pothof on fetal and neonatal alloimmune thrombocytopenia
    Mar 31 2025

    Dr Romy Pothof and Prof Joanne Verweij join us to discuss their development of an international consensus on the diagnosis and treatment of fetal and neonatal alloimmune thrombocytopenia.

    Read the full article:

    https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00029-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Show more Show less
    18 mins
No reviews yet